IGF2BP3 and breast carcinoma: Table 1 shows that the positivity rate of IGF2BP3 in grade III breast cancer patients (24.3%, 25/103) was significantly higher compared to patients in grades II (4.9%, 9/183) and I (0.0%, 0/13) (P<0.001).